Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 21:00:02 01/05/2024 BST 5-day change 1st Jan Change
13.74 USD -5.50% Intraday chart for Bausch + Lomb Corporation -7.79% -19.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year MT
Bausch + Lomb Q1 Loss Widens, Revenue Increases MT
Transcript : Bausch + Lomb Corporation, Q1 2024 Earnings Call, May 01, 2024
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million MT
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement MT
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes MT
Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes CI
RBC Previews Bausch Health's Q1, Trims Target to US$11 MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1 MT
Bausch + Lomb Q1 Results Likely to be Impacted by Foreign Exchange Headwinds, RBC Says MT
RBC Cuts Price Target on Bausch + Lomb to $18 From $20, Keeps Outperform Rating MT
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating MT
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Bausch + Lomb Brief: Says Will Present New Scientific Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Bausch + Lomb Corporation Announces Board Changes CI
Barclays Raises Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating MT
Deutsche Bank on Bausch + Lomb's Q4 MT
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says MT
RBC Raises Bausch + Lomb Target to US$20, Reiterates Outperform, After Q4 MT
Chart Bausch + Lomb Corporation
More charts
Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
13.74 USD
Average target price
19.79 USD
Spread / Average Target
+44.01%
Consensus
  1. Stock Market
  2. Equities
  3. BLCO Stock
  4. News Bausch + Lomb Corporation
  5. Bausch + Lomb Introducing "Enhanced" Adult 50+ Eye Vitamin Formulation With Vitamin D